Mariner’s Xeris Biopharma Holdings XERS Stock Holding History

Mariner’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Buy	47,314 +24,233	+105%	+$155K	﹤0.01%	2664
2026 Q1	$134K	Buy	+23,081	New	+$153K	﹤0.01%	3268
2025 Q4	–	Sell	-10,404	Closed	-$84.7K	–	3833
2025 Q3	$84.7K	Sell	10,404 -1,333	-11%	-$8.86K	﹤0.01%	3389
2025 Q2	$54.8K	Sell	11,737 -29,617	-72%	-$136K	﹤0.01%	3334
2025 Q1	$227K	Buy	41,354 +11,054	+36%	+$44.6K	﹤0.01%	2892
2024 Q4	$103K	Hold	30,300	–	–	﹤0.01%	3180
2024 Q3	$86.4K	Sell	30,300 -36,755	-55%	-$94.4K	﹤0.01%	3116
2024 Q2	$151K	Sell	67,055 -31,016	-32%	-$62.5K	﹤0.01%	2864
2024 Q1	$217K	Sell	98,071 -31,319	-24%	-$81K	﹤0.01%	2702
2023 Q4	$304K	Sell	129,390 -62,354	-33%	-$115K	﹤0.01%	2341
2023 Q3	$357K	Buy	191,744 +10,857	+6%	+$24.9K	﹤0.01%	2006
2023 Q2	$474K	Sell	180,887 -350	-0.2%	-$891	﹤0.01%	1785
2023 Q1	$295K	Buy	181,237 +150,923	+498%	+$189K	﹤0.01%	2081
2022 Q4	$40K	Buy	30,314 +14	+0%	+$20	﹤0.01%	2631
2022 Q3	$47K	Buy	+30,300	New	+$50.1K	﹤0.01%	2317

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Mariner's XERS Position: Q2 2026 in Review

Mariner increased its Xeris Biopharma Holdings (XERS) stake by 105% in Q2 2026, buying an estimated $155K and bringing the position to 47,314 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

Mariner first reported a position in XERS in Q3 2022 and has held it in 15 quarters since. The position peaked at $474K in Q2 2023. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Mariner held 47,314 shares of Xeris Biopharma Holdings worth $375K as of Q2 2026.
Mariner bought 24,233 Xeris Biopharma Holdings shares in Q2 2026, an estimated $155K.
Xeris Biopharma Holdings made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2664 holding.
Mariner first reported a position in Xeris Biopharma Holdings in Q3 2022 and has held it in 15 quarters since.
Mariner's Xeris Biopharma Holdings position peaked at $474K in Q2 2023.
241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.